nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—SLC22A2—Cisplatin—bone cancer	0.107	0.28	CbGbCtD
Cladribine—ABCG2—Carboplatin—bone cancer	0.0923	0.242	CbGbCtD
Cladribine—ABCG2—Cisplatin—bone cancer	0.0789	0.206	CbGbCtD
Cladribine—ABCG2—Doxorubicin—bone cancer	0.0529	0.138	CbGbCtD
Cladribine—ABCG2—Methotrexate—bone cancer	0.0512	0.134	CbGbCtD
Cladribine—POLE2—tendon—bone cancer	0.00173	0.0887	CbGeAlD
Cladribine—POLE2—bone marrow—bone cancer	0.00168	0.0859	CbGeAlD
Cladribine—RRM2B—connective tissue—bone cancer	0.00148	0.0757	CbGeAlD
Cladribine—POLE2—Idarubicin—Epirubicin—bone cancer	0.00114	0.123	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—bone cancer	0.00114	0.123	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—bone cancer	0.00114	0.123	CbGdCrCtD
Cladribine—PNP—bone marrow—bone cancer	0.00106	0.0543	CbGeAlD
Cladribine—POLE2—Epirubicin—Doxorubicin—bone cancer	0.00106	0.114	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—bone cancer	0.00106	0.114	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—bone cancer	0.00106	0.114	CbGdCrCtD
Cladribine—RRM2B—tendon—bone cancer	0.00102	0.0521	CbGeAlD
Cladribine—RRM2B—bone marrow—bone cancer	0.000986	0.0504	CbGeAlD
Cladribine—RRM2B—spinal cord—bone cancer	0.000982	0.0502	CbGeAlD
Cladribine—POLE3—tendon—bone cancer	0.000962	0.0492	CbGeAlD
Cladribine—POLE3—bone marrow—bone cancer	0.000932	0.0477	CbGeAlD
Cladribine—POLE3—spinal cord—bone cancer	0.000928	0.0475	CbGeAlD
Cladribine—PNP—Daunorubicin—Epirubicin—bone cancer	0.000881	0.0949	CbGdCrCtD
Cladribine—SLC28A3—bone marrow—bone cancer	0.000872	0.0446	CbGeAlD
Cladribine—PNP—Daunorubicin—Doxorubicin—bone cancer	0.000815	0.0878	CbGdCrCtD
Cladribine—POLE—tendon—bone cancer	0.000734	0.0375	CbGeAlD
Cladribine—POLE—bone marrow—bone cancer	0.000711	0.0364	CbGeAlD
Cladribine—POLA1—tendon—bone cancer	0.000633	0.0324	CbGeAlD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000625	0.00197	CbGpPWpGaD
Cladribine—POLA1—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000623	0.00196	CbGpPWpGaD
Cladribine—POLE—Mitotic G1-G1/S phases—DHFR—bone cancer	0.00062	0.00195	CbGpPWpGaD
Cladribine—POLA1—bone marrow—bone cancer	0.000613	0.0313	CbGeAlD
Cladribine—RRM2B—DNA Damage Response—TP53—bone cancer	0.000609	0.00192	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000607	0.00191	CbGpPWpGaD
Cladribine—RRM2—tendon—bone cancer	0.000604	0.0309	CbGeAlD
Cladribine—RRM2B—Direct p53 effectors—MDM2—bone cancer	0.000596	0.00188	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—bone cancer	0.000588	0.00185	CbGpPWpGaD
Cladribine—RRM2—E2F transcription factor network—PLAU—bone cancer	0.000587	0.00185	CbGpPWpGaD
Cladribine—RRM1—E2F transcription factor network—RB1—bone cancer	0.000586	0.00184	CbGpPWpGaD
Cladribine—RRM2—bone marrow—bone cancer	0.000586	0.0299	CbGeAlD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000586	0.00184	CbGpPWpGaD
Cladribine—POLE2—Synthesis of DNA—RB1—bone cancer	0.000577	0.00182	CbGpPWpGaD
Cladribine—PNP—Metabolism—NDUFA12—bone cancer	0.000571	0.0018	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—RFC1—bone cancer	0.000569	0.00179	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—CDK4—bone cancer	0.000564	0.00178	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TUBB4B—bone cancer	0.000561	0.00177	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—ZW10—bone cancer	0.000556	0.00175	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—NR1I2—bone cancer	0.000554	0.00174	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000553	0.00174	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—NT5C3A—bone cancer	0.000546	0.00172	CbGpPWpGaD
Cladribine—POLE2—S Phase—CDK4—bone cancer	0.000544	0.00171	CbGpPWpGaD
Cladribine—POLE2—DNA Replication—RB1—bone cancer	0.000541	0.0017	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—bone cancer	0.000541	0.0017	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—ZW10—bone cancer	0.000534	0.00168	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000532	0.00168	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—DHFR—bone cancer	0.000524	0.00165	CbGpPWpGaD
Cladribine—POLE2—G1/S Transition—RB1—bone cancer	0.000521	0.00164	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—JUN—bone cancer	0.000518	0.00163	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000515	0.00162	CbGpPWpGaD
Cladribine—DCK—Doxorubicin—Epirubicin—bone cancer	0.000514	0.0554	CbGdCrCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000509	0.0016	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—RFC1—bone cancer	0.000509	0.0016	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—ZW10—bone cancer	0.000509	0.0016	CbGpPWpGaD
Cladribine—POLE—DNA Repair—BRCA2—bone cancer	0.000506	0.00159	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000505	0.00159	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000503	0.00159	CbGpPWpGaD
Cladribine—RRM1—tendon—bone cancer	0.000502	0.0257	CbGeAlD
Cladribine—RRM2—Cell Cycle—ZW10—bone cancer	0.000497	0.00157	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000497	0.00156	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—RB1—bone cancer	0.00049	0.00154	CbGpPWpGaD
Cladribine—RRM1—bone marrow—bone cancer	0.000486	0.0249	CbGeAlD
Cladribine—RRM1—spinal cord—bone cancer	0.000484	0.0248	CbGeAlD
Cladribine—RRM2—E2F transcription factor network—RB1—bone cancer	0.000482	0.00152	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000482	0.00152	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—ZW10—bone cancer	0.000477	0.0015	CbGpPWpGaD
Cladribine—DCK—Epirubicin—Doxorubicin—bone cancer	0.000476	0.0513	CbGdCrCtD
Cladribine—PNP—Metabolism—NT5C3A—bone cancer	0.000473	0.00149	CbGpPWpGaD
Cladribine—POLE2—S Phase—RB1—bone cancer	0.000473	0.00149	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000463	0.00146	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000451	0.00142	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—bone cancer	0.000445	0.0014	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000444	0.0014	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000442	0.00139	CbGpPWpGaD
Cladribine—POLE2—Mitotic G1-G1/S phases—RB1—bone cancer	0.000439	0.00138	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000434	0.00137	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000421	0.00133	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000421	0.00133	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000419	0.00132	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—MDM2—bone cancer	0.000418	0.00132	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—EGFR—bone cancer	0.000407	0.00128	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000405	0.00127	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000402	0.00127	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000402	0.00127	CbGpPWpGaD
Cladribine—POLA1—E2F transcription factor network—PLAU—bone cancer	0.000402	0.00126	CbGpPWpGaD
Cladribine—Anorexia—Cisplatin—bone cancer	0.000395	0.00145	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000392	0.00123	CbGpPWpGaD
Cladribine—DCK—tendon—bone cancer	0.00039	0.02	CbGeAlD
Cladribine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00039	0.00144	CcSEcCtD
Cladribine—Hypotension—Cisplatin—bone cancer	0.000387	0.00143	CcSEcCtD
Cladribine—NR5A1—Gene Expression—FUS—bone cancer	0.000385	0.00121	CbGpPWpGaD
Cladribine—Abdominal discomfort—Methotrexate—bone cancer	0.000383	0.00141	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—RFC1—bone cancer	0.000382	0.0012	CbGpPWpGaD
Cladribine—Muscular weakness—Epirubicin—bone cancer	0.000382	0.00141	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—ZW10—bone cancer	0.00038	0.0012	CbGpPWpGaD
Cladribine—Pancytopenia—Methotrexate—bone cancer	0.00038	0.0014	CcSEcCtD
Cladribine—DCK—bone marrow—bone cancer	0.000378	0.0193	CbGeAlD
Cladribine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000377	0.00139	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TUBB4B—bone cancer	0.000377	0.00119	CbGpPWpGaD
Cladribine—Ataxia—Doxorubicin—bone cancer	0.000376	0.00139	CcSEcCtD
Cladribine—DCK—spinal cord—bone cancer	0.000376	0.0192	CbGeAlD
Cladribine—Neutropenia—Methotrexate—bone cancer	0.000374	0.00138	CcSEcCtD
Cladribine—POLE2—G1 to S cell cycle control—TP53—bone cancer	0.000372	0.00117	CbGpPWpGaD
Cladribine—POLE—Synthesis of DNA—RB1—bone cancer	0.000372	0.00117	CbGpPWpGaD
Cladribine—Paraesthesia—Cisplatin—bone cancer	0.000372	0.00137	CcSEcCtD
Cladribine—Upper respiratory tract infection—Methotrexate—bone cancer	0.000371	0.00137	CcSEcCtD
Cladribine—Eosinophilia—Epirubicin—bone cancer	0.00037	0.00136	CcSEcCtD
Cladribine—Dyspnoea—Cisplatin—bone cancer	0.000369	0.00136	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—RFC1—bone cancer	0.000367	0.00115	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TUBB4B—bone cancer	0.000362	0.00114	CbGpPWpGaD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000361	0.00133	CcSEcCtD
Cladribine—Decreased appetite—Cisplatin—bone cancer	0.00036	0.00133	CcSEcCtD
Cladribine—Pneumonia—Methotrexate—bone cancer	0.000358	0.00132	CcSEcCtD
Cladribine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000358	0.00132	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000357	0.00113	CbGpPWpGaD
Cladribine—Infestation—Methotrexate—bone cancer	0.000356	0.00131	CcSEcCtD
Cladribine—Infestation NOS—Methotrexate—bone cancer	0.000356	0.00131	CcSEcCtD
Cladribine—Pancytopenia—Epirubicin—bone cancer	0.000355	0.00131	CcSEcCtD
Cladribine—Pain—Cisplatin—bone cancer	0.000354	0.0013	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000353	0.0013	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—bone cancer	0.000353	0.0013	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—DHFR—bone cancer	0.000353	0.00111	CbGpPWpGaD
Cladribine—POLE—S Phase—CDK4—bone cancer	0.000351	0.0011	CbGpPWpGaD
Cladribine—Renal failure—Methotrexate—bone cancer	0.00035	0.00129	CcSEcCtD
Cladribine—RRM2—G1/S Transition—RB1—bone cancer	0.00035	0.0011	CbGpPWpGaD
Cladribine—Neutropenia—Epirubicin—bone cancer	0.00035	0.00129	CcSEcCtD
Cladribine—POLE—DNA Replication—RB1—bone cancer	0.000349	0.0011	CbGpPWpGaD
Cladribine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000348	0.00128	CcSEcCtD
Cladribine—Conjunctivitis—Methotrexate—bone cancer	0.000346	0.00128	CcSEcCtD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000343	0.00108	CbGpPWpGaD
Cladribine—Eosinophilia—Doxorubicin—bone cancer	0.000343	0.00126	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000342	0.00108	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—bone cancer	0.000342	0.00108	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—RFC1—bone cancer	0.000342	0.00108	CbGpPWpGaD
Cladribine—Feeling abnormal—Cisplatin—bone cancer	0.000341	0.00126	CcSEcCtD
Cladribine—POLA1—Cell Cycle—ZW10—bone cancer	0.00034	0.00107	CbGpPWpGaD
Cladribine—RRM2—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000339	0.00107	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Methotrexate—bone cancer	0.000337	0.00124	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—bone cancer	0.000336	0.00124	CcSEcCtD
Cladribine—POLE—G1/S Transition—RB1—bone cancer	0.000336	0.00106	CbGpPWpGaD
Cladribine—Pneumonia—Epirubicin—bone cancer	0.000335	0.00124	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000334	0.00105	CbGpPWpGaD
Cladribine—Infestation NOS—Epirubicin—bone cancer	0.000333	0.00123	CcSEcCtD
Cladribine—Infestation—Epirubicin—bone cancer	0.000333	0.00123	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000331	0.00122	CcSEcCtD
Cladribine—POLA1—E2F transcription factor network—RB1—bone cancer	0.00033	0.00104	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00033	0.00104	CbGpPWpGaD
Cladribine—Pancytopenia—Doxorubicin—bone cancer	0.000329	0.00121	CcSEcCtD
Cladribine—RRM1—Metabolism—NDUFA12—bone cancer	0.000328	0.00103	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—RFC1—bone cancer	0.000328	0.00103	CbGpPWpGaD
Cladribine—Renal failure—Epirubicin—bone cancer	0.000328	0.00121	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—bone cancer	0.000327	0.00121	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000326	0.00103	CbGpPWpGaD
Cladribine—Urinary tract infection—Epirubicin—bone cancer	0.000324	0.00119	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—bone cancer	0.000324	0.00119	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—bone cancer	0.000324	0.00119	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000322	0.00119	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—bone cancer	0.000321	0.00118	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—bone cancer	0.00032	0.00118	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—bone cancer	0.000317	0.00117	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—bone cancer	0.000316	0.00116	CcSEcCtD
Cladribine—POLE2—Cell Cycle—DHFR—bone cancer	0.000315	0.000994	CbGpPWpGaD
Cladribine—Hepatobiliary disease—Epirubicin—bone cancer	0.000315	0.00116	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—bone cancer	0.000315	0.00116	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—bone cancer	0.000314	0.00116	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000312	0.000983	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000311	0.000981	CbGpPWpGaD
Cladribine—Pneumonia—Doxorubicin—bone cancer	0.00031	0.00114	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—bone cancer	0.000309	0.00114	CcSEcCtD
Cladribine—Infestation—Doxorubicin—bone cancer	0.000309	0.00114	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000306	0.00113	CcSEcCtD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000306	0.000962	CbGpPWpGaD
Cladribine—Hypersensitivity—Cisplatin—bone cancer	0.000305	0.00112	CcSEcCtD
Cladribine—POLE—S Phase—RB1—bone cancer	0.000305	0.000961	CbGpPWpGaD
Cladribine—Renal failure—Doxorubicin—bone cancer	0.000303	0.00112	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—bone cancer	0.000302	0.00111	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—bone cancer	0.000301	0.00111	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—bone cancer	0.0003	0.00111	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—bone cancer	0.0003	0.00111	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—bone cancer	0.000299	0.0011	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—bone cancer	0.000299	0.0011	CcSEcCtD
Cladribine—Asthenia—Cisplatin—bone cancer	0.000297	0.00109	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—bone cancer	0.000297	0.00109	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—bone cancer	0.000297	0.00109	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—bone cancer	0.000296	0.00109	CcSEcCtD
Cladribine—RRM2—Mitotic G1-G1/S phases—RB1—bone cancer	0.000295	0.000929	CbGpPWpGaD
Cladribine—Oedema peripheral—Epirubicin—bone cancer	0.000295	0.00109	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—bone cancer	0.000294	0.00108	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—bone cancer	0.000293	0.00108	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000292	0.00108	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—bone cancer	0.000291	0.00107	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—bone cancer	0.00029	0.00107	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—bone cancer	0.000289	0.00106	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—bone cancer	0.000288	0.00106	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000288	0.000908	CbGpPWpGaD
Cladribine—Chills—Methotrexate—bone cancer	0.000287	0.00106	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000287	0.000903	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000284	0.000893	CbGpPWpGaD
Cladribine—Diarrhoea—Cisplatin—bone cancer	0.000283	0.00104	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—RB1—bone cancer	0.000283	0.000892	CbGpPWpGaD
Cladribine—Erythema multiforme—Epirubicin—bone cancer	0.000283	0.00104	CcSEcCtD
Cladribine—Alopecia—Methotrexate—bone cancer	0.000283	0.00104	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—bone cancer	0.00028	0.00103	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—bone cancer	0.00028	0.00103	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00028	0.000881	CbGpPWpGaD
Cladribine—Malnutrition—Methotrexate—bone cancer	0.000278	0.00103	CcSEcCtD
Cladribine—Erythema—Methotrexate—bone cancer	0.000278	0.00103	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—bone cancer	0.000278	0.00103	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—bone cancer	0.000278	0.00102	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—bone cancer	0.000277	0.00102	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—bone cancer	0.000275	0.00101	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—bone cancer	0.000274	0.00101	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—bone cancer	0.000273	0.00101	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—bone cancer	0.000272	0.001	CcSEcCtD
Cladribine—RRM1—Metabolism—NT5C3A—bone cancer	0.000272	0.000856	CbGpPWpGaD
Cladribine—Angiopathy—Epirubicin—bone cancer	0.000272	0.001	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—bone cancer	0.000272	0.001	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—bone cancer	0.00027	0.000996	CcSEcCtD
Cladribine—RRM2—Metabolism—NDUFA12—bone cancer	0.00027	0.000851	CbGpPWpGaD
Cladribine—Mediastinal disorder—Epirubicin—bone cancer	0.00027	0.000994	CcSEcCtD
Cladribine—Back pain—Methotrexate—bone cancer	0.000269	0.000992	CcSEcCtD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000269	0.000846	CbGpPWpGaD
Cladribine—Chills—Epirubicin—bone cancer	0.000269	0.00099	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—bone cancer	0.000267	0.000985	CcSEcCtD
Cladribine—NR5A1—Gene Expression—NR1I2—bone cancer	0.000267	0.00084	CbGpPWpGaD
Cladribine—POLA1—Synthesis of DNA—RB1—bone cancer	0.000265	0.000835	CbGpPWpGaD
Cladribine—Alopecia—Epirubicin—bone cancer	0.000265	0.000975	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CHEK2—bone cancer	0.000264	0.00083	CbGpPWpGaD
Cladribine—Vomiting—Cisplatin—bone cancer	0.000263	0.00097	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—bone cancer	0.000262	0.000966	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—bone cancer	0.000262	0.000965	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—RFC1—bone cancer	0.000261	0.000823	CbGpPWpGaD
Cladribine—Rash—Cisplatin—bone cancer	0.000261	0.000962	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—bone cancer	0.000261	0.000961	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—bone cancer	0.000261	0.00096	CcSEcCtD
Cladribine—Erythema—Epirubicin—bone cancer	0.000261	0.00096	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—bone cancer	0.000259	0.000954	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—bone cancer	0.000258	0.000952	CcSEcCtD
Cladribine—POLA1—Cell Cycle—TUBB4B—bone cancer	0.000258	0.000812	CbGpPWpGaD
Cladribine—Anaemia—Methotrexate—bone cancer	0.000257	0.000948	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—bone cancer	0.000257	0.000947	CcSEcCtD
Cladribine—Flatulence—Epirubicin—bone cancer	0.000257	0.000946	CcSEcCtD
Cladribine—DCK—Metabolism—NDUFA12—bone cancer	0.000253	0.000795	CbGpPWpGaD
Cladribine—Back pain—Epirubicin—bone cancer	0.000252	0.000929	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—bone cancer	0.000251	0.000926	CcSEcCtD
Cladribine—Malaise—Methotrexate—bone cancer	0.000251	0.000925	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—bone cancer	0.00025	0.000922	CcSEcCtD
Cladribine—POLA1—S Phase—CDK4—bone cancer	0.00025	0.000787	CbGpPWpGaD
Cladribine—Mediastinal disorder—Doxorubicin—bone cancer	0.00025	0.00092	CcSEcCtD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000249	0.000784	CbGpPWpGaD
Cladribine—POLA1—DNA Replication—RB1—bone cancer	0.000249	0.000783	CbGpPWpGaD
Cladribine—Chills—Doxorubicin—bone cancer	0.000249	0.000916	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—bone cancer	0.000247	0.000912	CcSEcCtD
Cladribine—Nausea—Cisplatin—bone cancer	0.000246	0.000906	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—bone cancer	0.000245	0.000902	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000244	0.00077	CbGpPWpGaD
Cladribine—Cough—Methotrexate—bone cancer	0.000243	0.000895	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—bone cancer	0.000243	0.000894	CcSEcCtD
Cladribine—Ill-defined disorder—Epirubicin—bone cancer	0.000242	0.000891	CcSEcCtD
Cladribine—Erythema—Doxorubicin—bone cancer	0.000241	0.000888	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—bone cancer	0.000241	0.000888	CcSEcCtD
Cladribine—Anaemia—Epirubicin—bone cancer	0.000241	0.000887	CcSEcCtD
Cladribine—POLE—G1 to S cell cycle control—TP53—bone cancer	0.00024	0.000755	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—RB1—bone cancer	0.000239	0.000754	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—ENO2—bone cancer	0.000239	0.000753	CbGpPWpGaD
Cladribine—Flatulence—Doxorubicin—bone cancer	0.000238	0.000875	CcSEcCtD
Cladribine—Chest pain—Methotrexate—bone cancer	0.000237	0.000873	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—bone cancer	0.000237	0.000873	CcSEcCtD
Cladribine—Myalgia—Methotrexate—bone cancer	0.000237	0.000873	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000237	0.000746	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—DHFR—bone cancer	0.000237	0.000746	CbGpPWpGaD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000235	0.000867	CcSEcCtD
Cladribine—Malaise—Epirubicin—bone cancer	0.000235	0.000866	CcSEcCtD
Cladribine—Discomfort—Methotrexate—bone cancer	0.000234	0.000863	CcSEcCtD
Cladribine—POLA1—Cell Cycle—RFC1—bone cancer	0.000234	0.000736	CbGpPWpGaD
Cladribine—Back pain—Doxorubicin—bone cancer	0.000233	0.000859	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000232	0.000731	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000231	0.000729	CbGpPWpGaD
Cladribine—Confusional state—Methotrexate—bone cancer	0.000229	0.000844	CcSEcCtD
Cladribine—Cough—Epirubicin—bone cancer	0.000227	0.000838	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—DHFR—bone cancer	0.000227	0.000716	CbGpPWpGaD
Cladribine—Infection—Methotrexate—bone cancer	0.000226	0.000832	CcSEcCtD
Cladribine—RRM2—Metabolism—NT5C3A—bone cancer	0.000224	0.000705	CbGpPWpGaD
Cladribine—Ill-defined disorder—Doxorubicin—bone cancer	0.000224	0.000824	CcSEcCtD
Cladribine—POLE2—Cell Cycle—BRCA2—bone cancer	0.000223	0.000704	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000223	0.000702	CbGpPWpGaD
Cladribine—Nervous system disorder—Methotrexate—bone cancer	0.000223	0.000821	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—bone cancer	0.000223	0.000821	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—bone cancer	0.000223	0.00082	CcSEcCtD
Cladribine—RRM2B—Metabolism—DHFR—bone cancer	0.000222	0.000699	CbGpPWpGaD
Cladribine—Chest pain—Epirubicin—bone cancer	0.000222	0.000817	CcSEcCtD
Cladribine—Myalgia—Epirubicin—bone cancer	0.000222	0.000817	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—bone cancer	0.000222	0.000817	CcSEcCtD
Cladribine—Anxiety—Epirubicin—bone cancer	0.000221	0.000815	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—bone cancer	0.000221	0.000813	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00022	0.000812	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—bone cancer	0.00022	0.000809	CcSEcCtD
Cladribine—Discomfort—Epirubicin—bone cancer	0.000219	0.000808	CcSEcCtD
Cladribine—Malaise—Doxorubicin—bone cancer	0.000217	0.000801	CcSEcCtD
Cladribine—POLA1—S Phase—RB1—bone cancer	0.000217	0.000685	CbGpPWpGaD
Cladribine—Anorexia—Methotrexate—bone cancer	0.000217	0.000798	CcSEcCtD
Cladribine—POLE2—Mitotic M-M/G1 phases—RB1—bone cancer	0.000215	0.000679	CbGpPWpGaD
Cladribine—Confusional state—Epirubicin—bone cancer	0.000214	0.00079	CcSEcCtD
Cladribine—Oedema—Epirubicin—bone cancer	0.000213	0.000784	CcSEcCtD
Cladribine—Hypotension—Methotrexate—bone cancer	0.000212	0.000782	CcSEcCtD
Cladribine—RRM2—Cell Cycle—DHFR—bone cancer	0.000212	0.000667	CbGpPWpGaD
Cladribine—Infection—Epirubicin—bone cancer	0.000211	0.000778	CcSEcCtD
Cladribine—ABCG2—bone marrow—bone cancer	0.000211	0.0108	CbGeAlD
Cladribine—Cough—Doxorubicin—bone cancer	0.00021	0.000775	CcSEcCtD
Cladribine—ABCG2—spinal cord—bone cancer	0.00021	0.0107	CbGeAlD
Cladribine—DCK—Metabolism—NT5C3A—bone cancer	0.000209	0.000659	CbGpPWpGaD
Cladribine—Nervous system disorder—Epirubicin—bone cancer	0.000209	0.000768	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—bone cancer	0.000208	0.000767	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—bone cancer	0.000208	0.000765	CcSEcCtD
Cladribine—PNP—Metabolism—ENO2—bone cancer	0.000207	0.000653	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GNA11—bone cancer	0.000207	0.000653	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000207	0.000763	CcSEcCtD
Cladribine—Skin disorder—Epirubicin—bone cancer	0.000207	0.000761	CcSEcCtD
Cladribine—Hyperhidrosis—Epirubicin—bone cancer	0.000206	0.000758	CcSEcCtD
Cladribine—Insomnia—Methotrexate—bone cancer	0.000206	0.000757	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—bone cancer	0.000205	0.000756	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—bone cancer	0.000205	0.000756	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—bone cancer	0.000205	0.000756	CcSEcCtD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000205	0.000646	CbGpPWpGaD
Cladribine—Anxiety—Doxorubicin—bone cancer	0.000205	0.000754	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—bone cancer	0.000204	0.000752	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000204	0.000751	CcSEcCtD
Cladribine—POLE—Cell Cycle—DHFR—bone cancer	0.000203	0.00064	CbGpPWpGaD
Cladribine—Discomfort—Doxorubicin—bone cancer	0.000203	0.000747	CcSEcCtD
Cladribine—Anorexia—Epirubicin—bone cancer	0.000203	0.000747	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—bone cancer	0.000203	0.000747	CcSEcCtD
Cladribine—Somnolence—Methotrexate—bone cancer	0.000202	0.000744	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—RB1—bone cancer	0.000202	0.000635	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000201	0.000633	CbGpPWpGaD
Cladribine—Hypotension—Epirubicin—bone cancer	0.000199	0.000732	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—bone cancer	0.000198	0.000731	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—bone cancer	0.000198	0.000728	CcSEcCtD
Cladribine—NR5A1—Gene Expression—EIF2S1—bone cancer	0.000197	0.00062	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000197	0.00062	CbGpPWpGaD
Cladribine—Oedema—Doxorubicin—bone cancer	0.000197	0.000725	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000196	0.000723	CcSEcCtD
Cladribine—Fatigue—Methotrexate—bone cancer	0.000196	0.000722	CcSEcCtD
Cladribine—Infection—Doxorubicin—bone cancer	0.000195	0.00072	CcSEcCtD
Cladribine—Pain—Methotrexate—bone cancer	0.000194	0.000716	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000194	0.000714	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—bone cancer	0.000193	0.000711	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—bone cancer	0.000193	0.00071	CcSEcCtD
Cladribine—PNP—Metabolism—DHFR—bone cancer	0.000192	0.000606	CbGpPWpGaD
Cladribine—Insomnia—Epirubicin—bone cancer	0.000192	0.000709	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—bone cancer	0.000192	0.000708	CcSEcCtD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000192	0.000604	CbGpPWpGaD
Cladribine—Skin disorder—Doxorubicin—bone cancer	0.000191	0.000704	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—bone cancer	0.000191	0.000704	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—bone cancer	0.00019	0.000701	CcSEcCtD
Cladribine—Dyspnoea—Epirubicin—bone cancer	0.00019	0.000699	CcSEcCtD
Cladribine—Somnolence—Epirubicin—bone cancer	0.000189	0.000697	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—MET—bone cancer	0.000189	0.000595	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CDK4—bone cancer	0.000189	0.000595	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CYP3A4—bone cancer	0.000188	0.000592	CbGpPWpGaD
Cladribine—Anorexia—Doxorubicin—bone cancer	0.000188	0.000691	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—bone cancer	0.000187	0.00069	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—bone cancer	0.000186	0.000685	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDK4—bone cancer	0.000185	0.000584	CbGpPWpGaD
Cladribine—Decreased appetite—Epirubicin—bone cancer	0.000185	0.000681	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—bone cancer	0.000184	0.000678	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000184	0.000677	CcSEcCtD
Cladribine—Fatigue—Epirubicin—bone cancer	0.000183	0.000676	CcSEcCtD
Cladribine—Pain—Epirubicin—bone cancer	0.000182	0.00067	CcSEcCtD
Cladribine—Constipation—Epirubicin—bone cancer	0.000182	0.00067	CcSEcCtD
Cladribine—Urticaria—Methotrexate—bone cancer	0.000181	0.000665	CcSEcCtD
Cladribine—PNP—Metabolism—GNA11—bone cancer	0.00018	0.000566	CbGpPWpGaD
Cladribine—Abdominal pain—Methotrexate—bone cancer	0.00018	0.000662	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—bone cancer	0.00018	0.000662	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000179	0.000661	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—bone cancer	0.000178	0.000656	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CHEK2—bone cancer	0.000177	0.000557	CbGpPWpGaD
Cladribine—Paraesthesia—Doxorubicin—bone cancer	0.000177	0.000651	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000176	0.000554	CbGpPWpGaD
Cladribine—Dyspnoea—Doxorubicin—bone cancer	0.000175	0.000646	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—bone cancer	0.000175	0.000646	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—bone cancer	0.000175	0.000645	CcSEcCtD
Cladribine—Gastrointestinal pain—Epirubicin—bone cancer	0.000174	0.000641	CcSEcCtD
Cladribine—NR5A1—Gene Expression—EZH2—bone cancer	0.000171	0.000539	CbGpPWpGaD
Cladribine—Decreased appetite—Doxorubicin—bone cancer	0.000171	0.00063	CcSEcCtD
Cladribine—POLE—Cell Cycle—CHEK2—bone cancer	0.00017	0.000535	CbGpPWpGaD
Cladribine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00017	0.000626	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—bone cancer	0.00017	0.000625	CcSEcCtD
Cladribine—Urticaria—Epirubicin—bone cancer	0.000169	0.000623	CcSEcCtD
Cladribine—Constipation—Doxorubicin—bone cancer	0.000168	0.00062	CcSEcCtD
Cladribine—Pain—Doxorubicin—bone cancer	0.000168	0.00062	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—bone cancer	0.000168	0.000619	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—bone cancer	0.000168	0.000619	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—bone cancer	0.000167	0.000617	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000167	0.000525	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDK4—bone cancer	0.000166	0.000522	CbGpPWpGaD
Cladribine—Asthenia—Methotrexate—bone cancer	0.000163	0.000601	CcSEcCtD
Cladribine—PNP—Metabolism—CYP3A4—bone cancer	0.000163	0.000513	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—bone cancer	0.000162	0.000597	CcSEcCtD
Cladribine—POLA1—Cell Cycle, Mitotic—DHFR—bone cancer	0.000162	0.00051	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—RB1—bone cancer	0.000161	0.000508	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000161	0.000593	CcSEcCtD
Cladribine—RRM2B—Metabolism—GSTP1—bone cancer	0.000161	0.000506	CbGpPWpGaD
Cladribine—Pruritus—Methotrexate—bone cancer	0.000161	0.000592	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000158	0.000498	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP2—bone cancer	0.000158	0.000496	CbGpPWpGaD
Cladribine—Hypersensitivity—Epirubicin—bone cancer	0.000157	0.000577	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—bone cancer	0.000156	0.000576	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—bone cancer	0.000156	0.000573	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—bone cancer	0.000156	0.000573	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—bone cancer	0.000155	0.000573	CcSEcCtD
Cladribine—Asthenia—Epirubicin—bone cancer	0.000153	0.000562	CcSEcCtD
Cladribine—Pruritus—Epirubicin—bone cancer	0.00015	0.000554	CcSEcCtD
Cladribine—Dizziness—Methotrexate—bone cancer	0.00015	0.000554	CcSEcCtD
Cladribine—RRM2—Cell Cycle—BRCA2—bone cancer	0.00015	0.000472	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—bone cancer	0.000146	0.000536	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—bone cancer	0.000145	0.000534	CcSEcCtD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000145	0.000456	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—DHFR—bone cancer	0.000145	0.000456	CbGpPWpGaD
Cladribine—Vomiting—Methotrexate—bone cancer	0.000144	0.000532	CcSEcCtD
Cladribine—POLE2—Cell Cycle—RB1—bone cancer	0.000144	0.000454	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—BRCA2—bone cancer	0.000144	0.000453	CbGpPWpGaD
Cladribine—Rash—Methotrexate—bone cancer	0.000143	0.000528	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—bone cancer	0.000143	0.000527	CcSEcCtD
Cladribine—Headache—Methotrexate—bone cancer	0.000142	0.000525	CcSEcCtD
Cladribine—Asthenia—Doxorubicin—bone cancer	0.000141	0.00052	CcSEcCtD
Cladribine—Dizziness—Epirubicin—bone cancer	0.000141	0.000518	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.00014	0.000442	CbGpPWpGaD
Cladribine—PNP—Metabolism—GSTP1—bone cancer	0.000139	0.000439	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—bone cancer	0.000139	0.000513	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—RB1—bone cancer	0.000139	0.000437	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—bone cancer	0.000135	0.000498	CcSEcCtD
Cladribine—Nausea—Methotrexate—bone cancer	0.000135	0.000497	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—bone cancer	0.000135	0.000496	CcSEcCtD
Cladribine—Rash—Epirubicin—bone cancer	0.000134	0.000494	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—bone cancer	0.000134	0.000494	CcSEcCtD
Cladribine—Headache—Epirubicin—bone cancer	0.000133	0.000491	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000133	0.000418	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00013	0.00041	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—bone cancer	0.00013	0.000479	CcSEcCtD
Cladribine—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000129	0.000407	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000128	0.000403	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—bone cancer	0.000126	0.000465	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000126	0.000396	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—bone cancer	0.000125	0.000461	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CDK4—bone cancer	0.000124	0.000392	CbGpPWpGaD
Cladribine—Rash—Doxorubicin—bone cancer	0.000124	0.000457	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—bone cancer	0.000124	0.000457	CcSEcCtD
Cladribine—Headache—Doxorubicin—bone cancer	0.000123	0.000454	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MDM2—bone cancer	0.000123	0.000387	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CHEK2—bone cancer	0.000121	0.000381	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CDK4—bone cancer	0.000119	0.000376	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000119	0.000375	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ENO2—bone cancer	0.000119	0.000375	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP9—bone cancer	0.000118	0.000373	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—bone cancer	0.000117	0.000431	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000113	0.000357	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000112	0.000351	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CDK4—bone cancer	0.000111	0.00035	CbGpPWpGaD
Cladribine—RRM1—Metabolism—DHFR—bone cancer	0.00011	0.000348	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00011	0.000348	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—RB1—bone cancer	0.000108	0.000341	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDK4—bone cancer	0.000107	0.000336	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—RB1—bone cancer	0.000104	0.000327	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GNA11—bone cancer	0.000103	0.000325	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000103	0.000324	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—BRCA2—bone cancer	0.000103	0.000323	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NDUFA12—bone cancer	0.000101	0.000318	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NDUFA12—bone cancer	0.0001	0.000315	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—RB1—bone cancer	9.89e-05	0.000312	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ENO2—bone cancer	9.81e-05	0.000309	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—RB1—bone cancer	9.67e-05	0.000305	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—EGFR—bone cancer	9.57e-05	0.000301	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CYP3A4—bone cancer	9.36e-05	0.000295	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NDUFA12—bone cancer	9.32e-05	0.000294	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—RB1—bone cancer	9.29e-05	0.000292	CbGpPWpGaD
Cladribine—DCK—Metabolism—ENO2—bone cancer	9.17e-05	0.000289	CbGpPWpGaD
Cladribine—RRM2—Metabolism—DHFR—bone cancer	9.1e-05	0.000287	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.91e-05	0.00028	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDK4—bone cancer	8.51e-05	0.000268	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GNA11—bone cancer	8.5e-05	0.000268	CbGpPWpGaD
Cladribine—DCK—Metabolism—DHFR—bone cancer	8.5e-05	0.000268	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NT5C3A—bone cancer	8.37e-05	0.000264	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—bone cancer	8.33e-05	0.000262	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NT5C3A—bone cancer	8.29e-05	0.000261	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MDM2—bone cancer	8.25e-05	0.00026	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	8.11e-05	0.000255	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTP1—bone cancer	8.01e-05	0.000252	CbGpPWpGaD
Cladribine—DCK—Metabolism—GNA11—bone cancer	7.95e-05	0.00025	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MDM2—bone cancer	7.92e-05	0.000249	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NT5C3A—bone cancer	7.72e-05	0.000243	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP3A4—bone cancer	7.71e-05	0.000243	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDK4—bone cancer	7.61e-05	0.00024	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	7.56e-05	0.000238	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.48e-05	0.000235	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—RB1—bone cancer	7.4e-05	0.000233	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—bone cancer	7.22e-05	0.000227	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP3A4—bone cancer	7.2e-05	0.000227	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—bone cancer	7.05e-05	0.000222	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	6.8e-05	0.000214	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—RB1—bone cancer	6.62e-05	0.000208	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTP1—bone cancer	6.59e-05	0.000208	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	6.34e-05	0.0002	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—bone cancer	6.22e-05	0.000196	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTP1—bone cancer	6.16e-05	0.000194	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—bone cancer	5.79e-05	0.000182	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MDM2—bone cancer	5.64e-05	0.000178	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MDM2—bone cancer	5.21e-05	0.000164	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MDM2—bone cancer	4.85e-05	0.000153	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—bone cancer	4.73e-05	0.000149	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—bone cancer	4.54e-05	0.000143	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—bone cancer	4.15e-05	0.000131	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—bone cancer	3.67e-05	0.000116	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—bone cancer	3.63e-05	0.000114	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—bone cancer	3.42e-05	0.000108	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—DHFR—bone cancer	3.4e-05	0.000107	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—bone cancer	3.38e-05	0.000107	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—DHFR—bone cancer	3.37e-05	0.000106	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—bone cancer	3.24e-05	0.000102	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—bone cancer	3.19e-05	0.000101	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GNA11—bone cancer	3.18e-05	0.0001	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GNA11—bone cancer	3.15e-05	9.91e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—DHFR—bone cancer	3.14e-05	9.88e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GNA11—bone cancer	2.93e-05	9.24e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP3A4—bone cancer	2.88e-05	9.08e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP3A4—bone cancer	2.85e-05	8.99e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP3A4—bone cancer	2.66e-05	8.38e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—bone cancer	2.47e-05	7.77e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—bone cancer	2.44e-05	7.69e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—bone cancer	2.27e-05	7.16e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—bone cancer	1.28e-05	4.02e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—bone cancer	1.26e-05	3.98e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—bone cancer	1.18e-05	3.71e-05	CbGpPWpGaD
